The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma, a rare form of bone cancer with no FDA-approved treatments. The coveted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback